October 25 is MDS World Awareness Day. We stand with everyone living with blood cancer — this month and every day.

Publications & Presentations

Advancing scientific understanding from research to real-world evidence.
Every study contributes to a deeper understanding of blood cancer and the potential for new treatment approaches. Through clinical trials, real-world evidence, investigator-sponsored research, and scientific collaboration, Geron is committed to generating evidence that may help advance science, inform clinical practice, and improve outcomes for people living with blood cancer.

Explore our scientific publications and presentations:

This page may contain non-exhaustive scientific information about post-hoc, exploratory, subgroup analyses, or uses that have not yet been approved by regulatory authorities. The information is provided for educational and scientific exchange purposes only, and does not suggest products should be used in a manner not consistent with their respective label approved by the regulatory authorities, which may differ by geography. Any publication reflects the state of knowledge at the time it was published. The information is not medical advice and cannot replace the independent medical judgement of a healthcare professional.

Journal articles

Telomerase Inhibition With Imetelstat in Patients With Lower-Risk Myelodysplastic Syndromes: Integrating Molecular Findings, Cytopenias, and Clinical Outcomes

DGHO

October 9, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Durable Clinical Outcomes With Imetelstat (IME) in Korean Patients (Pts) With Lower-Risk (LR)-MDS

JSH

October 9, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Real-World Experience With Imetelstat in Lower-Risk Myelodysplastic Syndromes: Insights From United States Claims Data

JSH

October 9, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Real-World Data

Combining the Telomerase Inhibitor Imetelstat with the BCL-2 Inhibitor Venetoclax Enhances Apoptosis and Improves Survival in Acute Myeloid Leukemia Cellular and Animal Models

Journal of Clinical Medicine

September 23, 2026
Acute Myeloid Leukemia (AML)Preclinical Data

Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial

Blood Neoplasia

April 16, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes

Blood Cancer Journal

April 7, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial

British Journal of Haematology

February 1, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study

Haematologica

January 22, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat

Nature Leukemia

January 12, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS

Blood Cancer Journal

December 31, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic Syndromes

Clinical and Translational Science

December 14, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Plain language summary of IMerge, a Phase 3 studyof imetelstat versus placebo in people with lower-risk myelodysplastic syndromes and anemia

Future Oncology

October 12, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Conference presentations

Improvement of Patient-Reported Fatigue in IMerge Phase 3 Trial of Imetelstat versus Placebo in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory/Ineligible to Erythropoiesis Stimulating Agents

AMCP Nexus 2023

October 17, 2023
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Disease Modifying Activity of Imetelstat in Patients with Heavily Transfused Non-del (5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase 3

SOHO 2023

September 8, 2023
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Improvement of Patient-Reported Fatigue in IMerge Phase 3 Trial of Imetelstat vs. Placebo in Heavily Transfused Non-del (5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents

SOHO 2023

September 8, 2023
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Continuous Transfusion Independence with Imetelstat in Heavily Transfused Non-del (5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase 3

SOHO 2023

September 8, 2023
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Disease Modifying Activity of Imetelstat in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis Stimulating Agents in IMerge Phase 3

EHA 2023

June 12, 2023
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Continuous Transfusion Independence with Imetelstat in Lower Risk MDS in IMerge Phase 3

EHA 2023

June 12, 2023
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Analysis of Patient Reported Fatigue in IMerge Phase 3 Trial of Imetelstat vs. Placebo in Lower Risk MDS

EHA 2023

June 12, 2023
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Modulation of the immune landscape in lower-risk myelodysplastic syndromes with imetelstat-induced transfusion independency

EHA 2023

June 12, 2023
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

The telomerase inhibitor imetelstat differentially targets JAK2V617F- versus CALR-mutant Myeloproliferative Neoplasm cells and inhibits JAK-STAT signaling

EHA 2023

June 12, 2023
Clinical Data

IMerge: Results From a Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Imetelstat in Patients with Lower-Risk MDS

IMerge: Results From a Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Imetelstat in Patients With Heavily Transfusion Dependent Non…

ASCO 2023

June 3, 2023
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate-1, Intermediate-2 or High-Risk Myelofibrosis

ASH 2022

December 5, 2022
Myelofibrosis (MF)Clinical Data

MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

ASH 2022

December 5, 2022
Myelofibrosis (MF)Clinical Data